SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided an update on its strategic progress since its last capital raise in September 2024. The Company also announced the appointment of Janet Huffman as its new interim Chief Executive Officer. Strategic Progress Since Capital Raise Following the Company's $4 million capital raise in September 2024, the Company has made significant advancements, including: Formulation and Device Enhancements: The Company has improved the formulation and intranasal delivery device for ONP-002 and in connection therewith

TRxADE Health, Inc. today announced that it changed its name and ticker symbol to "Scienture Holdings, Inc." and "SCNX", respectively, and that the business will continue as a Nasdaq-listed company. TAMPA, FL, Sept. 24, 2024 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. (the "Company") (NASDAQ:MEDS) and Scienture, LLC ("Scienture"), a wholly owned subsidiary of the Company, today announced that the Company has changed its name to "Scienture Holdings, Inc." Effective as of September 23, 2024, the Company's stock is now trading on the Nasdaq Stock Market LLC under the new ticker symbol "SCNX". Scienture Holdings, Inc., through its wholly owned subsidiaries, Scienture and Integra Pharma Solutions

TAMPA, FL and COMMACK, NY, Sept. 20, 2024 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. ("TRxADE") (NASDAQ:MEDS) and Scienture, LLC ("Scienture"), a wholly owned subsidiary of TRxADE, today announced that it is changing its name to Scienture Holdings, Inc. ("Scienture Holdings"), effective Monday, September 23, 2024. Scienture Holdings stock will begin trading under the new ticker symbol NASDAQ:SCNX on September 23, 2024. About TRxADE TRxADE HEALTH, INC. historically focused on health services IT assets and operations aimed at digitalizing the retail pharmacy experience. Our current primary operations are conducted through our wholly-owned subsidiary, Integra Pharma Solutions, LLC ("IPS"), whi

TAMPA, FL and COMMACK, NY, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. ("TRxADE") (NASDAQ:MEDS) and Scienture, LLC ("Scienture"), a wholly owned subsidiary of TRxADE, today announced the appointment of Narasimhan Mani, Ph.D., MBA as Scienture's President. Shankar Hariharan, Ph.D., the current President and CEO, will be CEO of Scienture. Rahul Surana, Ph.D., MBA has been promoted to Executive VP and COO of Scienture. Dr. Narasimhan Mani is an experienced healthcare professional and a proven leader with over 25 years of experience in both the scientific and business areas of the pharmaceutical industry. He currently is a part of the Executives-in-Residence program at New Rhein Hea

Scienture, Inc., a private branded and specialty pharmaceutical company, entered into a business combination with TRxADE Health Inc., in an all-stock transaction valued at $103 million. TAMPA, FL and COMMACK, NY, July 26, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH, INC. ("TRxADE") (NASDAQ:MEDS) and Scienture, Inc. ("Scienture") today announced the closing of TRxADE's business combination with Scienture in an all-stock transaction (the "Business Combination"). TRxADE acquired all of Scienture's assets in exchange for shares of TRxADE stock, in a combination of common stock and non-voting convertible preferred stock. TRxADE will change its name to "Scienture Holdings, Inc." subsequent to the fu

TAMPA, FL, July 09, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH, INC. (NASDAQ:MEDS) (the "Company"), announced that the Company's board of directors has declared a special cash dividend of $1.50 per share of common stock. The special dividend is being paid using a portion of the proceeds received in May 2024 in connection with the prior sale of the Company's web-based market platform assets. The special cash dividend is payable to stockholders of record as of July 19, 2024, with the dividend being paid on or about July 24, 2024. Forward-Looking Statements This press release contains certain statements that may be deemed to be "forward-looking statements" within the federal securities laws, in

TAMPA, FL, June 27, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH Inc. (NASDAQ:MEDS) (the "Company"), announced today that with the filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the "Form 10-Q"), the Company regained compliance with Nasdaq listing rules and posted net income of over $21 million for the period in question due to the previously announced sale of substantially all of the assets of the Company's wholly-owned subsidiary Trxade, Inc. On May 23, 2024, the Company received a standard notice of noncompliance from the Nasdaq Listing Qualifications Department ("Nasdaq") indicating that, as a result of not having timely filed its Form 10-Q for the first qu

TAMPA, FL, May 29, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH, Inc. (NASDAQ:MEDS) (the "Company"), announced that, on May 23, 2024, the Company received a notice (the "Notice") from the Nasdaq Listing Qualifications Department ("Nasdaq") indicating that because the Company had not yet filed its Quarterly Report on Form 10-Q for the period ending March 31, 2024 (the "Form 10-Q"), the Company is not compliant with the timely filing requirement for continued listing under Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule"), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission. The Notice indicates that the Company must, no later

TAMPA, FL, April 23, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH, Inc. (NASDAQ:MEDS) (the "Company"), announced that, on April 17, 2024, the Company received a notice (the "Notice") from the Nasdaq Listing Qualifications Department ("Nasdaq") indicating that because the Company had not yet filed its Annual Report on Form 10-K for the 2023 fiscal year (the "Form 10-K"), the Company was not compliant with the timely filing requirement for continued listing under Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule"), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission. The Notice had no immediate effect on the listing or trading

TAMPA, FL, March 06, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH Inc. (NASDAQ:MEDS) (the "Company"), announced that the Company's board of directors has declared a special cash dividend of $8.00 per share of common stock. The special dividend is being paid using a portion of the proceeds from the closing of the recently announced sale of the Company's web-based market platform assets. The special cash dividend is payable to stockholders of record as of March 18, 2024, with the dividend being paid on or about March 22, 2024. Forward-Looking Statements This press release contains certain statements that may be deemed to be "forward-looking statements" within the federal securities laws, includi

8-K - Scienture Holdings, Inc. (0001382574) (Filer)

DEF 14C - TRxADE HEALTH, INC (0001382574) (Filer)

PRE 14C - TRxADE HEALTH, INC (0001382574) (Filer)

10-Q - TRxADE HEALTH, INC (0001382574) (Filer)

8-K - TRxADE HEALTH, INC (0001382574) (Filer)

8-K - TRxADE HEALTH, INC (0001382574) (Filer)

10-Q - TRxADE HEALTH, INC (0001382574) (Filer)

8-K - TRxADE HEALTH, INC (0001382574) (Filer)

8-K - TRxADE HEALTH, INC (0001382574) (Filer)

8-K - TRxADE HEALTH, INC (0001382574) (Filer)

SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided an update on its strategic progress since its last capital raise in September 2024. The Company also announced the appointment of Janet Huffman as its new interim Chief Executive Officer. Strategic Progress Since Capital Raise Following the Company's $4 million capital raise in September 2024, the Company has made significant advancements, including: Formulation and Device Enhancements: The Company has improved the formulation and intranasal delivery device for ONP-002 and in connection therewith

TAMPA, FL and COMMACK, NY, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. ("TRxADE") (NASDAQ:MEDS) and Scienture, LLC ("Scienture"), a wholly owned subsidiary of TRxADE, today announced the appointment of Narasimhan Mani, Ph.D., MBA as Scienture's President. Shankar Hariharan, Ph.D., the current President and CEO, will be CEO of Scienture. Rahul Surana, Ph.D., MBA has been promoted to Executive VP and COO of Scienture. Dr. Narasimhan Mani is an experienced healthcare professional and a proven leader with over 25 years of experience in both the scientific and business areas of the pharmaceutical industry. He currently is a part of the Executives-in-Residence program at New Rhein Hea

Forbes Fisher Appointed as Chief Operating Officer.Dr. Eugenio Bortone Appointed as Chief Innovation & Food Technology Officer. TAMPA, FL, Aug. 03, 2023 (GLOBE NEWSWIRE) -- TRxADE HEALTH, Inc (NASDAQ:MEDS), parent company of pharmaceutical B2B exchange platform, which recently merged with Superlatus, Inc today announced the appointments of Forbes Fisher as Chief Operating Officer and Dr. Eugenio (Gino) Bortone as Chief Innovation & Food Technology Officer. Forbes brings over 25 years of Food Services industry experience and will lead product innovation and information technology, and drive sales and supply chain optimization to support growth and profitability initiatives. Dr. Eugenio

TAMPA, FL, Oct. 03, 2022 (GLOBE NEWSWIRE) -- TRxADE HEALTH, INC. (NASDAQ:MEDS)("TRxADE" or the "Company"), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., announced today the appointment of Mr. Jeff Newell to the Company's Board of Directors. Prior to his appointment to the Board of Directors, Mr. Newell served on the Company's Advisory Board. Mr. Newell will serve as a strategic resource to TRxADE as it continues to develop its trade relationships in the industry. "We are thrilled to move industry expert, Mr. Newell from our Advisory board to our Board of D

TAMPA, FL / ACCESSWIRE / August 16, 2022 / TRxADE HEALTH, INC. (NASDAQ:MEDS) ("TRxADE" or the "Company"), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., announced today the appointment of Jeff Newell to the Company's advisory board. Mr. Newell is expected to serve as a strategic resource to TRxADE as it continues to develop trade relationships in the industry."We are thrilled to add industry experts like Mr. Newell to the Advisory Board and look forward to working with him to build stockholder value," said Suren Ajjarapu, Chairman of the Board, who continued, "We

Experienced energy industry and finance executive to serve as Chairman of IEC's Audit Committee JAKARTA, INDONESIA AND DANVILLE, CA / ACCESSWIRE / January 25, 2021 / Indonesia Energy Corporation (NYSE American:INDO) ("IEC"), an oil and gas exploration and production company focused on Indonesia, today announced that the company's Board of Directors has appointed Michael L. Peterson to the Board. Mr. Peterson will serve as an independent Board member and will also serve as the Chairman of the Audit Committee of the Board of Directors. Mr. Peterson has over 30 years of experience in executive management positions in all aspects of the energy industry and finance industries, having served as

SC 13G/A - TRxADE HEALTH, INC (0001382574) (Subject)

SC 13G - TRxADE HEALTH, INC (0001382574) (Subject)

SC 13D/A - TRxADE HEALTH, INC (0001382574) (Subject)

SC 13D/A - TRxADE HEALTH, INC (0001382574) (Subject)

TAMPA, FL, July 09, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH, INC. (NASDAQ:MEDS) (the "Company"), announced that the Company's board of directors has declared a special cash dividend of $1.50 per share of common stock. The special dividend is being paid using a portion of the proceeds received in May 2024 in connection with the prior sale of the Company's web-based market platform assets. The special cash dividend is payable to stockholders of record as of July 19, 2024, with the dividend being paid on or about July 24, 2024. Forward-Looking Statements This press release contains certain statements that may be deemed to be "forward-looking statements" within the federal securities laws, in

TAMPA, FL, March 06, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH Inc. (NASDAQ:MEDS) (the "Company"), announced that the Company's board of directors has declared a special cash dividend of $8.00 per share of common stock. The special dividend is being paid using a portion of the proceeds from the closing of the recently announced sale of the Company's web-based market platform assets. The special cash dividend is payable to stockholders of record as of March 18, 2024, with the dividend being paid on or about March 22, 2024. Forward-Looking Statements This press release contains certain statements that may be deemed to be "forward-looking statements" within the federal securities laws, includi

Spero is another addition to the growing Superlatus CPG portfolio under their Urgent Company umbrella of brands.Spero® is a plant-based tech company specializing in alternative dairy and egg replacements, on a mission to outcompete traditional dairy and egg products in scale, price, taste, and nutrition by utilizing internationally patent-pending technologies that transforms low-cost, sustainable, and scalable ingredients into plant-based alternatives. Spero's mission is to scale mainstream dairy alternatives and have them be delicious, affordable, and available to everyone, everywhere. TAMPA, FL, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Superlatus, Inc. ("Superlatus"), wholly owned subsidary of

TAMPA, FL, Aug. 14, 2023 (GLOBE NEWSWIRE) -- TRxADE HEALTH, Inc. (NASDAQ:MEDS) ("TRxADE"), a pharmaceutical exchange platform provider, today announced that it has filed for an extension to file its Quarterly Report on Form 10-Q for Q2 pursuant to a Form 12b-25 filed with the SEC. The Company is not able to timely file its 10-Q by August 14, 2023, the original due date for such filing, without unreasonable effort or expense, because additional time is required to finalize its financial statements and related disclosures required to be included in the 10-Q in connection with the recent merger transaction it completed in July. TRxADE will release financial results for the second quarter 202

TAMPA, FL / ACCESSWIRE / July 31, 2023 / TRxADE HEALTH INC. (NASDAQ:MEDS), is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., will release financial results for the second quarter 2023, after market close on August 14, 2023. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.In addition, management will host a conference call on Monday, August 14th, 2023, at 6:00 p.m. Eastern time to discuss TRxADE HEALTH's second quarter 2023 financial results. The call will conclud

Continues Nationwide Expansion of Breakthrough Digital Healthcare Services IT Platform TAMPA, FL, May 15, 2023 (GLOBE NEWSWIRE) -- TRxADE HEALTH, INC. (NASDAQ:MEDS) ("TRxADE" or the "Company"), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., today announced its financial results for the quarter ended March 31, 2023. 2023 and Subsequent Operational Highlights TRxADE continued to expand the TRxADE drug procurement marketplace nationwide, increasing new members approximately 1,100 for the first quarter of 2023 compared to the first quarter of 2022, bringing the t

TAMPA, FL / ACCESSWIRE / May 5, 2023 / TRxADE HEALTH INC. (NASDAQ:MEDS), is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., will release financial results for the first quarter 2023, after market close on May 15, 2023. Please note that this is a revised date from the original reporting date of May 8, 2023. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.In addition, management will host a conference call on Monday, May 15, 2023, at 6:00 p.m. Eastern time to discus

TAMPA, FL / ACCESSWIRE / April 25, 2023 / TRxADE HEALTH INC. (NASDAQ:MEDS), is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., will release financial results for the first quarter 2023, after market close on May 8, 2023. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.In addition, management will host a conference call on Monday, May 8, 2023, at 5:00 p.m. Eastern time to discuss TRxADE HEALTH's first quarter 2023 financial results. The call will conclude with a Q&

Continues Nationwide Expansion of Breakthrough Digital Healthcare Services IT PlatformTAMPA, FL / ACCESSWIRE / March 27, 2023 / TRxADE HEALTH, INC. (NASDAQ:MEDS) ("TRxADE" or the "Company"), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., today announced its financial results for the year ended December 31, 2022.2022 and Subsequent Operational HighlightsTRxADE continued to expand the TRxADE drug procurement marketplace nationwide, adding 1,212 new registered members during fiscal 2022, bringing the total registered members to approximately 14,400+ at December 31, 2

TAMPA, FL / ACCESSWIRE / March 13, 2023 / TRxADE HEALTH INC. (NASDAQ:MEDS), is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., will release financial results for fourth quarter and year-end 2022, after market close on March 27, 2023. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.In addition, management will host a conference call on Monday, March 27, 2023, at 5:30 p.m. Eastern time to discuss TRxADE HEALTH's fourth quarter and year-end 2022 financial results. Th